What Silexion Therapeutics Corp does.

Unless the context otherwise requires, in this “Business” section, the terms “we,” “us” and “our” generally refer to: (i) for the period following the Closing of the Business Combination on August 15, 2024, Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (“Silexion”) and its consolidated subsidiaries, including Silexion Therapeutics Ltd., an Israeli company (“Silexion Israel”), through which our business is primarily conducted, and, (ii) with respect to all periods prior to and through the Closing of the Business Combination, Silexion Israel and its subsidiaries.

We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (“ KRAS ”). The KRAS gene, when mutated, plays a central role in many cancer types, such as pancreatic, colorectal and lung, and is therefore considered to be an oncogene. This oncogene instructs cells to make the corresponding KRAS protein which has a controlling function in cell growth signaling in the cancer cells. While multiple pharmaceutical companies are pursuing strategies to inhibit or tag the KRAS protein for degradation and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling— we silence the KRAS oncogene itself, preventing the production of the oncogenic protein.

Revenue and profit, by fiscal year.

More on SLXN.

• Silexion Therapeutics Corp summary
• Silexion Therapeutics Corp financial statements
• Silexion Therapeutics Corp key metrics
• Silexion Therapeutics Corp health scores and style box
• Silexion Therapeutics Corp earnings
• Silexion Therapeutics Corp dividends
• Silexion Therapeutics Corp valuation
• Silexion Therapeutics Corp ownership and insiders
• Silexion Therapeutics Corp peers

Figures from Silexion Therapeutics Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.